# Scientific Paper Quantitative Evaluation Report

## 1. Basic Info

- Title: ARIS: Autonomous Research via Adversarial Multi-Agent Collaboration
- Venue: arXiv / Hugging Face paper page
- Year: 2026
- Field: AI agent / research automation
- Paper type: system paper
- Evaluator: not assigned
- Date: not evaluated
- Rubric: `scientific_paper_evaluation_v1`
- Canonical score record: `scientific_evaluation.yaml`

## 2. Final Scores

- Paper Quality Score: not evaluated
- Confidence Score: not evaluated
- Overclaim Risk: not evaluated
- Reproducibility Risk: not evaluated
- Decision: not evaluated

This report is intentionally not scored yet. The W19 work completed a reading
pass and a bounded claim-ledger fixture, but a full scientific-quality judgment
requires a separate claim-evidence pass over the paper, appendix, repository,
and any available benchmark or deployment evidence.

## 3. Dimension Scores

| Dimension | Score | Max |
| --- | ---: | ---: |
| Problem Value | 0 | 12 |
| Literature & Gap | 0 | 10 |
| Contribution & Novelty | 0 | 12 |
| Method Soundness | 0 | 16 |
| Evidence & Experiment | 0 | 20 |
| Results & Analysis | 0 | 10 |
| Reproducibility | 0 | 10 |
| Scientific Honesty | 0 | 6 |
| Communication | 0 | 4 |
| Total | 0 | 100 |

## 4. Claim-Evidence Matrix

| Claim | Evidence Provided | Evidence Strength | Comment |
| --- | --- | --- | --- |
| ARIS is a useful method reference for claim-ledger and reviewer-independence workflows. | W19 reading notes and local fixture. | Partial for local method transfer only. | This is enough for Idea OS method seeding, not enough for a final paper-quality score. |
| Cross-family review improves autonomous research quality. | Paper describes observational deployment evidence and a future controlled benchmark plan. | Not evaluated. | Needs a controlled claim-evidence pass before scoring. |
| Full ARIS reproduction is feasible locally. | Official repository exists, but W19 stopped before provider/API/MCP setup. | Not evaluated. | Reproducibility risk must be scored separately. |

## 5. Major Strengths

1. The paper appears highly aligned with research-agent assurance and evidence-audit workflows.
2. The claim-ledger idea produced a small local fixture for unsupported-success measurement.
3. The paper exposes a useful first-principles bottleneck: polished research-agent outputs need evidence-aware acceptance gates.

## 6. Major Weaknesses

1. The W19 pass has not yet completed a full claim-evidence matrix for the paper.
2. Controlled causal evidence for cross-family review has not been scored.
3. Full local reproducibility has not been attempted because credentialed provider orchestration was outside the bounded lab run.

## 7. Caps / Penalties Applied

| Rule | Applied? | Reason |
| --- | --- | --- |
| none | no | No final quality score has been assigned yet. |

## 8. Confidence Notes

- Full text: not locked for scoring
- Supplementary material: not checked for scoring
- Code / data / appendix: repository inspected only for run boundary
- Evaluator domain background: not declared
- Evidence-note completeness: not complete
- Second reviewer: not present
- Adjudication: not present

## 9. Overclaim And Reproducibility Risks

- Overclaim risk: not evaluated
- Reproducibility risk: not evaluated
- Most important unsupported or under-supported claim: cross-family review superiority under controlled cost and quality conditions.
- Most important reproducibility bottleneck: full ARIS orchestration may require provider/API/MCP setup beyond the W19 bounded fixture.

## 10. Final Judgment

Do not use a final accept/reject judgment yet. The next step is to convert the
paper into a full scientific-quality score by filling `scientific_evaluation.yaml`
with evidence-backed coefficients and then updating this report from the
validated score.
